{"name":"HK inno.N Corporation","slug":"hk-inno-n-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"oncology","drugs":[{"name":"A dose as CJ-15314","genericName":"A dose as CJ-15314","slug":"a-dose-as-cj-15314","indication":"Other","status":"phase_1"},{"name":"Amlodipine 5mg, Candesartan cilexetil 16mg","genericName":"Amlodipine 5mg, Candesartan cilexetil 16mg","slug":"amlodipine-5mg-candesartan-cilexetil-16mg","indication":"Other","status":"phase_3"},{"name":"CJ-40002","genericName":"CJ-40002","slug":"cj-40002","indication":"Other","status":"phase_1"},{"name":"CJ-40010 CVA16 vaccine C dose","genericName":"CJ-40010 CVA16 vaccine C dose","slug":"cj-40010-cva16-vaccine-c-dose","indication":"Other","status":"phase_1"},{"name":"B dose as CJ-15314","genericName":"B dose as CJ-15314","slug":"b-dose-as-cj-15314","indication":"Other","status":"phase_1"},{"name":"CJ-12420 formulation 1","genericName":"CJ-12420 formulation 1","slug":"cj-12420-formulation-1","indication":"Other","status":"phase_1"},{"name":"CJ-30061","genericName":"CJ-30061","slug":"cj-30061","indication":"Other","status":"phase_1"},{"name":"IN-115314 Ointment 1%","genericName":"IN-115314 Ointment 1%","slug":"in-115314-ointment-1","indication":"Other","status":"phase_2"},{"name":"IN-A012","genericName":"IN-A012","slug":"in-a012","indication":"Other","status":"phase_1"},{"name":"IN-C004 without water","genericName":"IN-C004 without water","slug":"in-c004-without-water","indication":"Other","status":"phase_1"},{"name":"Lansoprazole 15 mg","genericName":"Lansoprazole 15 mg","slug":"lansoprazole-15-mg","indication":"Other","status":"marketed"},{"name":"Lansoprazole Triple Therapy","genericName":"Lansoprazole Triple Therapy","slug":"lansoprazole-triple-therapy","indication":"Gastroesophageal reflux disease","status":"phase_2"},{"name":"Lansoprazole/Amoxicillin/Clarithromycin","genericName":"Lansoprazole/Amoxicillin/Clarithromycin","slug":"lansoprazole-amoxicillin-clarithromycin","indication":"Helicobacter pylori eradication in patients with peptic ulcer disease","status":"marketed"},{"name":"Period I : CJ30001, Period II : HKB0701 and SLM0807","genericName":"Period I : CJ30001, Period II : HKB0701 and SLM0807","slug":"period-i-cj30001-period-ii-hkb0701-and-slm0807","indication":"Other","status":"phase_1"},{"name":"RCN301","genericName":"RCN301","slug":"rcn301","indication":"Other","status":"phase_3"},{"name":"Tegoprazan/Amoxicillin/Clarithromycin","genericName":"Tegoprazan/Amoxicillin/Clarithromycin","slug":"tegoprazan-amoxicillin-clarithromycin","indication":"Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis","status":"phase_3"},{"name":"Xarlin (Levocetirizine)","genericName":"Xarlin (Levocetirizine)","slug":"xarlin-levocetirizine","indication":"Allergic rhinitis","status":"marketed"},{"name":"candesartan cilexetil 32mg, amlodipine 10mg","genericName":"candesartan cilexetil 32mg, amlodipine 10mg","slug":"candesartan-cilexetil-32mg-amlodipine-10mg","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"CJ-30001/CJ-30002","genericName":"CJ-30001/CJ-30002","slug":"cj-30001-cj-30002","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"IN-B00009","genericName":"IN-B00009","slug":"in-b00009","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RAPAE01","genericName":"RAPAE01","slug":"rapae01","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RPN301","genericName":"RPN301","slug":"rpn301","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"IN-C006 Peri inj.","genericName":"IN-C006 Peri inj.","slug":"in-c006-peri-inj","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"IN-C006 inj.","genericName":"IN-C006 inj.","slug":"in-c006-inj","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"A-prexa","genericName":"A-prexa","slug":"a-prexa","indication":"Treatment of schizophrenia","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CJ-12420/Clarithromycin/Amoxicillin","genericName":"CJ-12420/Clarithromycin/Amoxicillin","slug":"cj-12420-clarithromycin-amoxicillin","indication":"Helicobacter pylori infection (eradication therapy)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Candesartan cilexetil/Amlodipine besylate","genericName":"Candesartan cilexetil/Amlodipine besylate","slug":"candesartan-cilexetil-amlodipine-besylate","indication":"Hypertension (high blood pressure)","status":"marketed"}]}],"pipeline":[{"name":"A dose as CJ-15314","genericName":"A dose as CJ-15314","slug":"a-dose-as-cj-15314","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-prexa","genericName":"A-prexa","slug":"a-prexa","phase":"marketed","mechanism":"A-prexa is an antipsychotic medication that works by blocking dopamine receptors in the brain.","indications":["Treatment of schizophrenia","Treatment of bipolar disorder"],"catalyst":""},{"name":"Amlodipine 5mg, Candesartan cilexetil 16mg","genericName":"Amlodipine 5mg, Candesartan cilexetil 16mg","slug":"amlodipine-5mg-candesartan-cilexetil-16mg","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CJ-40002","genericName":"CJ-40002","slug":"cj-40002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CJ-40010 CVA16 vaccine C dose","genericName":"CJ-40010 CVA16 vaccine C dose","slug":"cj-40010-cva16-vaccine-c-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"B dose as CJ-15314","genericName":"B dose as CJ-15314","slug":"b-dose-as-cj-15314","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CJ-12420 formulation 1","genericName":"CJ-12420 formulation 1","slug":"cj-12420-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CJ-12420/Clarithromycin/Amoxicillin","genericName":"CJ-12420/Clarithromycin/Amoxicillin","slug":"cj-12420-clarithromycin-amoxicillin","phase":"phase_3","mechanism":"CJ-12420 is a novel compound combined with clarithromycin and amoxicillin to provide enhanced antimicrobial activity, likely through synergistic bacterial cell wall disruption and protein synthesis inhibition.","indications":["Helicobacter pylori infection (eradication therapy)"],"catalyst":""},{"name":"CJ-30001/CJ-30002","genericName":"CJ-30001/CJ-30002","slug":"cj-30001-cj-30002","phase":"phase_3","mechanism":"CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"CJ-30061","genericName":"CJ-30061","slug":"cj-30061","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candesartan cilexetil/Amlodipine besylate","genericName":"Candesartan cilexetil/Amlodipine besylate","slug":"candesartan-cilexetil-amlodipine-besylate","phase":"marketed","mechanism":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.","indications":["Hypertension (high blood pressure)"],"catalyst":""},{"name":"IN-115314 Ointment 1%","genericName":"IN-115314 Ointment 1%","slug":"in-115314-ointment-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IN-A012","genericName":"IN-A012","slug":"in-a012","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IN-B00009","genericName":"IN-B00009","slug":"in-b00009","phase":"phase_3","mechanism":"This drug is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"IN-C004 without water","genericName":"IN-C004 without water","slug":"in-c004-without-water","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IN-C006 Peri inj.","genericName":"IN-C006 Peri inj.","slug":"in-c006-peri-inj","phase":"phase_3","mechanism":"IN-C006 Peri inj. is a drug that targets the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"IN-C006 inj.","genericName":"IN-C006 inj.","slug":"in-c006-inj","phase":"phase_3","mechanism":"IN-C006 inj. is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Lansoprazole 15 mg","genericName":"Lansoprazole 15 mg","slug":"lansoprazole-15-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lansoprazole Triple Therapy","genericName":"Lansoprazole Triple Therapy","slug":"lansoprazole-triple-therapy","phase":"phase_2","mechanism":"Inhibits the H+/K+ ATPase enzyme in the gastric parietal cells","indications":["Gastroesophageal reflux disease","Peptic ulcer disease"],"catalyst":""},{"name":"Lansoprazole/Amoxicillin/Clarithromycin","genericName":"Lansoprazole/Amoxicillin/Clarithromycin","slug":"lansoprazole-amoxicillin-clarithromycin","phase":"marketed","mechanism":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis.","indications":["Helicobacter pylori eradication in patients with peptic ulcer disease","H. pylori-associated gastritis"],"catalyst":""},{"name":"Period I : CJ30001, Period II : HKB0701 and SLM0807","genericName":"Period I : CJ30001, Period II : HKB0701 and SLM0807","slug":"period-i-cj30001-period-ii-hkb0701-and-slm0807","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RAPAE01","genericName":"RAPAE01","slug":"rapae01","phase":"phase_3","mechanism":"RAPAE01 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RCN301","genericName":"RCN301","slug":"rcn301","phase":"phase_3","mechanism":"RCN301 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"RPN301","genericName":"RPN301","slug":"rpn301","phase":"phase_3","mechanism":"RPN301 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"Tegoprazan/Amoxicillin/Clarithromycin","genericName":"Tegoprazan/Amoxicillin/Clarithromycin","slug":"tegoprazan-amoxicillin-clarithromycin","phase":"phase_3","mechanism":"This triple-therapy combination uses tegoprazan to reduce gastric acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.","indications":["Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis"],"catalyst":""},{"name":"Xarlin (Levocetirizine)","genericName":"Xarlin (Levocetirizine)","slug":"xarlin-levocetirizine","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms.","indications":["Allergic rhinitis","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"candesartan cilexetil 32mg, amlodipine 10mg","genericName":"candesartan cilexetil 32mg, amlodipine 10mg","slug":"candesartan-cilexetil-32mg-amlodipine-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5HMkJVQ3dsczhPQXBPWHlEMU94WU9vdUJCV1pxNEdudzVEZkJmRDNaUTNqeV84bFRTVnJXMk4wMGFRVnQtWkF5cGwxM04zdm5FUnRwUGIxVzZqbEtvWHZILVlQa0lVOVZXNzJmeVlfZGNkRjY1?oc=5","date":"2026-02-12","type":"pipeline","source":"Businesskorea","summary":"Eight Domestic Pharma Companies Exceed 1 Trillion Won Sales Last Year - Businesskorea","headline":"Eight Domestic Pharma Companies Exceed 1 Trillion Won Sales Last Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9BeWp6Mi02U1ZYVE1qbnJNekZSc1hSUDVYV2JRVWIxY3JGVUZQZ20xTjVsQ1FUVzVpX25makZPNTR1UEVBMGV0Y0lLUzNFUm9seml3MlByb2hfZE1jUkVuOUw0elJuSk5JNXFtcllR0gFyQVVfeXFMUGtBZGZ6MnF4aDFaZG5TcFdwOVdoNmZTaTctSlBUMHJoenYtUEF0TnlXVkNZYU85VGlCb29WbWRoLTI3N2ZLMTlFdFhzdXFQdzItQUhEbE5Ub0JuTXJDcmhrcy1hQXlwMjJ5YnFXZ1Y4anJR?oc=5","date":"2026-01-07","type":"regulatory","source":"koreabiomed.com","summary":"K-drugmakers including HLB, HK inno.N face pivotal year in US FDA race - koreabiomed.com","headline":"K-drugmakers including HLB, HK inno.N face pivotal year in US FDA race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1jb2VWMV9VYWQ5QmpoS0huUUwxMFR6TDYtOW13WVNnWWRmM243MVIzRlVYdjFicThCNlpUOWRLQVFLanRLWTlZUC02SXVZMzRQRTJlVUJhVXFnSTN1MGdlS0RNWXVNejBMaHhFLVNR0gFyQVVfeXFMT0c3NjNQT3BqWG4zX0JjTThXT09ONmw1bHc3YkJDZVZiT2pxOGdCeWQzRFRPaThVZUZhUUhFQXRMaWR0ak0zNjVTVlcyTDFlSXpVVG4xUGZkOGIzYWRsaE0yQ3c2czN0ODlXYW5PY0htbXpn?oc=5","date":"2025-12-15","type":"deal","source":"koreabiomed.com","summary":"HK inno.N buys Japan rights to K-CAB, becomes RaQualia’s top shareholder - koreabiomed.com","headline":"HK inno.N buys Japan rights to K-CAB, becomes RaQualia’s top shareholder","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-16","type":"pipeline","source":"The Hindu","summary":"Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India - The Hindu","headline":"Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5IeE81Zzh2X0xYMjYyZ0E0eDFCSWJhUmZSUlg1RTdTanhQOFNVZmpTLWtscjNyZTBZdlVfbGFZSFJRd2FuSFFxRFJNUmNYSVZGeDJSYzlIN0VSVF9DTjl3bWhHSldBRUlXR1hzWGdn0gFyQVVfeXFMUGpxNXlDY2RLWXVaaDMxYWVyT1RLSTJSd2M0elFSd29lTUEycnpueThpWEFpRkZhamxPMnNSMDJudV9tdkZ5U3FrOU1SakpEaUxoOGhkdGRmNU5kcEtHOHIteHNNRlhJUVlKMmUwSlV0amVB?oc=5","date":"2025-03-24","type":"pipeline","source":"koreabiomed.com","summary":"HK inno.N becomes largest shareholder of Japan’s RaQualia to boost R&D, K-CAB expansion - koreabiomed.com","headline":"HK inno.N becomes largest shareholder of Japan’s RaQualia to boost R&D, K-CAB expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOTU5c19VWXc2TGV1OGJFRXBfMDJmaC02QlNuRXgwUkJneWc4X0djcHNfRkx2N2FuaDM2ZFAwRUM4YWxXd1R4QXZwZV9rZjk4dzRxTFZfRlY4NXBDNXVwR1p0emRuWWc4R2t1QV9qSEpfQ3VkV3otejd6MFY1V0d0cGRUS2h4ZU9aUUI0bExlTlVjQ295VmhnVmxUN3dXZnB4UjMzMjhJdmR1bGQ4THpXSWd3RENUTXlUbzc1eU5EUDdiN0tSZ3VhNVFJMGlTRXhabExDczl0cVo3Zw?oc=5","date":"2024-05-07","type":"deal","source":"BioPharma APAC","summary":"Sciwind Biosciences and HK inno.N Forge Partnership to Bring New Diabetes Treatment to South Korea - BioPharma APAC","headline":"Sciwind Biosciences and HK inno.N Forge Partnership to Bring New Diabetes Treatment to South Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE80WlNRd212bzJMYzhMUDRkTmJESnIzYjZ6Y3AwYUZCTktLUE9EZ2RZMjBQYlZqSkZvRGdia2ZqdmNIaUJWNXRxLXUyanFOaWFPWXVNeGNVc0t1cF84cFh0Ty1aRTdtdzB2UEx5TmZR?oc=5","date":"2024-04-23","type":"pipeline","source":"KED Global","summary":"HK inno.N to release K-CAB in MENA market - KED Global","headline":"HK inno.N to release K-CAB in MENA market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9aNjZBRFNUeHJHOWNtTWNCTGNMTlFYcGFNRzVmRjAzb2VMZTdHT3pTSUdsaW1fNEk0YnY2eVg0Y0lwNDdMQmdvUURvSm9Pbk1XYXhDaWE5blE1NzNiWUJVRUd1bFFpY0NReW1JRHFR0gFyQVVfeXFMTVM4S1RaenNVS0h0V0VBcmFESHc1NUdIX2pBM2FUdjJtN25JTWhMZWhtSEpNdXR5bmJrY094bFlDZkppSzRLWTRUcEpvWTlnRUVWUXlIaXJyQ0hwSWxMY1RoaFVIVGdJSmh6VjBsVXRkdUl3?oc=5","date":"2024-03-12","type":"patent","source":"koreabiomed.com","summary":"HK inno.N addresses growth concerns following patent suit setback - koreabiomed.com","headline":"HK inno.N addresses growth concerns following patent suit setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXZmdjazRZRVhEcHQtM3JudjRqQzhNNDU2VlpfNXhKQkl1MkVmOWVTdC1Ja1BPV3BFZ0pWZkRvdHJKbC1JQXFIaXNfbm1KWDQ4TUxWUDUycHBMRDVDbUJtNkpJZmpRaG0tTnJ3Q2Vn?oc=5","date":"2023-12-20","type":"pipeline","source":"KED Global","summary":"Boryung, HK inno.N to co-market Kanarb, K-CAB - KED Global","headline":"Boryung, HK inno.N to co-market Kanarb, K-CAB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9lZFNZZHowcTVKdXREOUNrOUdNMVBRdURTMzRmbFB5OFJTYndweTM0eUg3dGx4WXlpbFBWZS1RMl9RXzNtRl9IM1BySmJySlRMdmQzSXMwdWhFaUt0YndObFRtc0NXNU5VS3pvR21n?oc=5","date":"2023-07-10","type":"pipeline","source":"KED Global","summary":"HK inno.N releases new drug for GERD in Indonesia - KED Global","headline":"HK inno.N releases new drug for GERD in Indonesia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPRl9XZzAzcFpXRnhKSW5IUVdmYUFhdVlaaVg5NlJWOTVYOEFQbjhBVlZUREpTaVFUUDF2OVZRNGNPYUhiX0pPTEdZSng0MGJMdHNfclNqeGV0X1ZLeUlyRVJvVkNLdDRwTXNBMS00cWRHUURXbkd4THJReV96TzEyYjJZcE9HaHVZVnNJdnAtZjNuU1RlWlNBWUF6aU5qMnBmY0p3NmpXUjk0Y0FlRmsxR29vS3B2X3UxVUFjeGg3THhLY2dsdVRUY3kwWjBGYlhaN1dyYjY2RGs4Q0wtWjN2U2NUek95OEhLNjhyQ3NfQjNOT3RfQ1NMVWtWTDRmVFBIQjNkWGhR?oc=5","date":"2022-10-28","type":"deal","source":"prnewswire.com","summary":"Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada - prnewswire.com","headline":"Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Cana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE41bnJsSTFvSXBKRFdzZDlVQktENWE5WjFNSGFLVUxLYTBZd2NLdW9hSEZfd2lDa0dyOWViY1BOVnJSNnBTSDlnVTBsdUxYeXlqc2ZhVW9vQ3FXV21tOThBbHl5X00yZTFaWl9BclppcGtjaWdw?oc=5","date":"2021-12-24","type":"pipeline","source":"KED Global","summary":"HK inno.N’s K-CAB a blockbuster drug with $843 million exports - KED Global","headline":"HK inno.N’s K-CAB a blockbuster drug with $843 million exports","sentiment":"neutral"}],"patents":[],"drugCount":27,"phaseCounts":{"phase_1":10,"marketed":5,"phase_3":10,"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}